Daily Debrief: What Happened Today (Feb 6)

    • An artist’s impression of AstraZeneca’s planned new facility, which will make antibody drug conjugates used in cancer treatment. This was one of several precision medicine projects secured in 2024.
    • An artist’s impression of AstraZeneca’s planned new facility, which will make antibody drug conjugates used in cancer treatment. This was one of several precision medicine projects secured in 2024. ILLUSTRATION: ASTRAZENECA
    Published Thu, Feb 6, 2025 · 06:30 PM

    Stories you might have missed

    Singapore’s investment commitments in 2024 rose 6.3% to S$13.5 billion: EDB

    SINGAPORE attracted some S$13.5 billion in fixed asset investment (FAI) commitments in 2024, over half of which were in electronics, Singapore’s Economic Development Board (EDB) said at its annual year in review on Thursday (Feb 6).


    SGX seeing ‘improved momentum’ in IPO pipeline, hopeful that listings will exceed last year’s

    More companies could be listing here this year with the Singapore Exchange (SGX) seeing an improved pipeline of initial public offerings (IPOs), the bourse operator said.


    Malaysia rolls out bold tax perks for Johor-Singapore SEZ, eyeing high tech, talent

    BT in your inbox

    Start and end each day with the latest news stories and analyses delivered straight to your inbox.

    THE Malaysian Investment Development Authority (Mida) – a key government agency that drives investment into the manufacturing and services sectors – has unveiled a comprehensive tax incentive package for the Johor-Singapore Special Economic Zone (JS-SEZ), offering lucrative incentives to key sectors to attract investors and strengthen cross-border economic ties.


    Tariffs not the only driver of investment decision, ‘too early’ to tell its impact on Singapore: EDB

    IT IS “too early” to say if US investments into Singapore would be affected by tariffs meted out by the Trump administration, the chairman of Singapore’s Economic Development Board (EDB) said on Thursday (Feb 6).


    HSBC upgrades Grab to ‘buy’ on attractive valuations, growth drivers ahead

    HSBC upgraded its rating on ride-hailing giant Grab to a “buy” on attractive valuations and “intact” growth drivers, while Maybank maintained its buy rating.

    Copyright SPH Media. All rights reserved.